About us
- >
- About us >
- Information >
- Announcement
2019-06-17
The phase II trial of ENERGI-F703 gel for diabetic foot ulcer treatment has achieved the goal of target patient enrollment.
With the approval of FDA and TFDA, the phase II trial of ENERGI-F703 gel for diabetic foot ulcer treatment has achieved the goal of target patient enrollment on 14th of June, 2019. The clinical trial will evaluate the efficacy of ENERGI-F703 gel in subjects with diabetic foot ulcer.